Istituto Oncologico Veneto
Padova, Italy/Padova, 35128, Italy
Location status: Recruiting
NCT Number: NCT06941194
Patients will be recruited at the time of the pre-admission visit. During the screening visit the patient will undergo a physical examination and his medical history will be collected. Oncological history and tumor characteristics will be considered and CT-scan imaging will be analysed. ECOG performance status will be reported. If inclusion criteria are respected, the patient will be randomized. The application of the PICO14 study device or standard dressing (dry gauze and plaster) will then be carried out on the day of surgery. For subjects randomized to the treatment arm (Arm A), dressing change with the application of the new PICO14 will occur at day 4+1, day 8±1, and day 14±2. For subjects randomized to the control arm (Arm B), the standard dressing with gauze and plaster is applied. Regardless of the randomization arm the wound assessment via ASEPSIS score will occur at day 4+1, 8±1 and 14±2. During FUP, the dressing can be changed autonomously by the patient if necessary. The information will be recorded on the occasion of the next visit or an extraordinary visit. On day 21, sutures will be removed.
On day 30±2, the total ASEPSIS score will be calculated, in order to evaluate the wound healing.
From day 14±2, regardless of the randomization arm all patients will be treated with standard dressing.
Follow-up visits can be scheduled up to 90 days after surgery.
Interested in participating?
Request Info18 year–99 year
All sexes
Interventional
Not applicable
Padova, Italy/Padova, 35128, Italy
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PICO 14 application after neoadjuvant radiotherapy followed by surgery
Time frame: Through study completion, an average of 2 years
Assess, in patients with wide excision surgery of radio treated limb sarcoma, if the preventive application of single-use negative pressure wound dressing (PICO 14) may reduce the incidence of wound complications at 30° day compared to the standard procedure currently in use. Primary objective will be evaluated according to the ASEPSIS score. For each patient the Daily ASEPSIS score will be calculated at days 4, 8 and 14 after surgery.
Time frame: Through study completion, an average of 2 years
Evaluate and compare the incidence of long-term wound complications. All complications occurred between day 31 and day 90 after surgery will be collected and reported at the time of appearance, by ASEPSIS score
Time frame: Through study completion, an average of 2 years
Verify the impact of the type of wound dressing in the length of hospital-stay. 2. The length of hospital stay will be calculated as the difference between the date of hospital discharge and the date of surgery
Time frame: Through study completion, an average of 2 years
Evaluate the outpatient care time. 3. Outpatient care time will be calculated as the difference between the date of the last outpatient medication and the date of discharge.
Contact information is provided by the study sponsor or research team.
Istituto Oncologico Veneto IRCCS
Other
Preventive Application of Single-use Negative Pressure Wound Therapy (sNPWT) in the Postoperative Course of Radiotreatated Limb Sarcoma Surgery a Randomized Clinical Trial
Acronym: PRALISS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04577014
Neoplasms, Neoplasms by Histologic Type
New York, United States
View Trial DetailsNCT04122872
Carcinosarcoma, Neoplasms
Tübingen, Baden-Wurttemberg, Germany
View Trial DetailsNCT07066982
DNA Virus Infections, Hemic and Lymphatic Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06637007
Neoplasms, Neoplasms by Histologic Type
Taiyuan, Shanxi, China
View Trial Details